Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib in Surgically Resectable, Chemotherapy-Resistant, Triple Negative Breast Cancer
NCT03979508Phase 2Terminated
- Sponsor
- Mayo Clinic
- Start
- Jan 2020
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of abemaciclib in triple-negative breast cancer (TNBC) (2 cohorts), sponsored by Mayo Clinic. Primary endpoint: Number of Patients Who Have a CD8/FOXP3 Ratio < 1.6 in Their Residual Tumors After Neoadjuvant Chemotherapy (NAC) That Convert to CD8/FOXP3 Ratio >= 1.6 at 21 days. Started Jan 2020; status: terminated.
02
Drugs
abemaciclib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03979508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03979508.